AMTAGVI Gets FDA Patent Boost: Challenge by August 2026
Published Date: 2/13/2026
Notice
Summary
The FDA has officially set the review period for AMTAGVI, a new human biological product, so its patent can be extended. This affects the company behind AMTAGVI and anyone interested in patent timing or drug availability. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 14 or August 12, 2026, to speak up—so don’t miss these deadlines!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
AMTAGVI Review Period Set
The FDA determined AMTAGVI's regulatory review period is 3,306 days in total: 2,969 days in the testing phase and 337 days in the approval phase. FDA verified the testing phase began on January 30, 2015, the biologics license application was submitted on March 17, 2023, and the application was approved on February 16, 2024. This determination establishes the maximum potential length of a patent extension; the applicant is seeking 42 days of patent term extension and the USPTO will apply statutory limits when calculating the actual extension.
Deadlines To Challenge Dates
Anyone who believes the published dates are incorrect may submit comments and ask for a redetermination by April 14, 2026. Any interested person may petition FDA about whether the patent applicant acted with due diligence during the regulatory review period by August 12, 2026, and petitions must meet the requirements of 21 CFR 60.30 and related filing rules.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-02973 — Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY
The FDA has officially set the review period for CRENESSITY, a new drug, so its patent can be extended. This helps the drug maker get extra time to protect their invention, which could affect when generic versions hit the market. If anyone thinks the dates are wrong or wants to challenge the drug maker’s speed during review, they have until April 14 or August 12, 2026, to speak up.
Next: 2026-02976 — Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI
The FDA has set the official review period for KEBILIDI, a human biological product, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially affecting when generic versions can enter the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until April or August 2026 to speak up.